Our Exciting Journey to ACT-451840

Our Exciting Journey to ACT-451840

We describe our work resulting in the selection of ACT-451840 ( 38 ) as a novel antimalarial drug with a novel mode of action. The compound was broadly characterized in vitro as well as in vivo in rat PK experiments as well as two different mouse malaria models. In the P. berghei infected mouse mode...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christoph Boss, Sergio Wittlin
Formato: article
Lenguaje:DE
EN
FR
Publicado: Swiss Chemical Society 2021
Materias:
academia-industry collaboration
act-451840
drug discovery
malaria
medicinal chemistry
Chemistry
QD1-999
Acceso en línea:https://doaj.org/article/93b7c702dfa74ab3aef04287a807090c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:93b7c702dfa74ab3aef04287a807090c
record_format dspace
spelling oai:doaj.org-article:93b7c702dfa74ab3aef04287a807090c2021-11-26T09:53:16ZOur Exciting Journey to ACT-45184010.2533/chimia.2021.9160009-42932673-2424https://doaj.org/article/93b7c702dfa74ab3aef04287a807090c2021-11-01T00:00:00Zhttps://doaj.org/toc/0009-4293https://doaj.org/toc/2673-2424We describe our work resulting in the selection of ACT-451840 ( 38 ) as a novel antimalarial drug with a novel mode of action. The compound was broadly characterized in vitro as well as in vivo in rat PK experiments as well as two different mouse malaria models. In the P. berghei infected mouse model cure could be achieved at oral doses of 300 mg/kg over 3 consecutive days. ACT-451840 was clinically investigated up to an experimental human malaria infection model, where therapeutic effects could be shown.Christoph BossSergio WittlinSwiss Chemical Societyarticleacademia-industry collaborationact-451840drug discoverymalariamedicinal chemistryChemistryQD1-999DEENFRCHIMIA, Vol 75, Iss 11, Pp 916-922 (2021)
institution DOAJ
collection DOAJ
language DE
EN
FR
topic academia-industry collaboration
act-451840
drug discovery
malaria
medicinal chemistry
Chemistry
QD1-999
spellingShingle academia-industry collaboration
act-451840
drug discovery
malaria
medicinal chemistry
Chemistry
QD1-999
Christoph Boss
Sergio Wittlin
Our Exciting Journey to ACT-451840
description We describe our work resulting in the selection of ACT-451840 ( 38 ) as a novel antimalarial drug with a novel mode of action. The compound was broadly characterized in vitro as well as in vivo in rat PK experiments as well as two different mouse malaria models. In the P. berghei infected mouse model cure could be achieved at oral doses of 300 mg/kg over 3 consecutive days. ACT-451840 was clinically investigated up to an experimental human malaria infection model, where therapeutic effects could be shown.
format article
author Christoph Boss
Sergio Wittlin
author_facet Christoph Boss
Sergio Wittlin
author_sort Christoph Boss
title Our Exciting Journey to ACT-451840
title_short Our Exciting Journey to ACT-451840
title_full Our Exciting Journey to ACT-451840
title_fullStr Our Exciting Journey to ACT-451840
title_full_unstemmed Our Exciting Journey to ACT-451840
title_sort our exciting journey to act-451840
publisher Swiss Chemical Society
publishDate 2021
url https://doaj.org/article/93b7c702dfa74ab3aef04287a807090c
work_keys_str_mv AT christophboss ourexcitingjourneytoact451840
AT sergiowittlin ourexcitingjourneytoact451840
_version_ 1718409670805159936

Ejemplares similares